Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - tablet - aripiprazole 5 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - tablet - aripiprazole 10 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - tablet - aripiprazole 15 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - tablet - aripiprazole 30 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 10 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 15 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 30 mg - psycholeptics

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - blinatumomab, quantity: 38.5 microgram/g - injection, solution - excipient ingredients: citric acid monohydrate; lysine hydrochloride; polysorbate 80; sodium hydroxide; water for injections - blincyto is indicated for the treatment of relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).,blincyto is indicated for the treatment of minimal residual disease (mrd) positive b-cell precursor acute lymphoblastic leukaemia (all) in patients in complete haematological remission.,note to indication: the indications in philadelphia positive, mrd positive and paediatric patients were approved based on phase ii, non-randomised evidence. an improvement in clinical outcomes by direct prospective comparison in a randomised setting relative to other standard-of-care salvage therapies has not been established.

Philippines - English - FDA (Food And Drug Administration)

euro-healthcare exponents, inc.; distributor: euro-healthcare exponents, inc. - vitamin b complex - solution for injection (im/iv) - 100mg/ 100mg/ 100mcg/ 100mg/ 50mg